<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has filed a regulatory disclosure with BSE and NSE confirming that it does not qualify as a 'Large Corporate' under the SEBI framework for fund raising through debt securities, for the period ending March 31, 2025. As per the disclosure, the company's outstanding borrowing stood at Rs. 84.31 Crores (un-audited) as on March 31, 2025, which is below the threshold that would trigger the Large Corporate classification. The filing is a routine compliance requirement under SEBI's Master Circular dated May 22, 2024, and the company explicitly states it is not obligated to raise funds via debt securities under this framework. The disclosure is signed by the Company Secretary and the CFO & Whole Time Director.
This is a routine compliance filing with no material impact on shareholders or the stock price. It simply confirms that the company's current borrowings are below the SEBI Large Corporate threshold, meaning no mandatory debt-instrument fundraising requirement applies. Investors should not read this as positive or negative news.